CO2021008218A2 - Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso - Google Patents
Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de usoInfo
- Publication number
- CO2021008218A2 CO2021008218A2 CONC2021/0008218A CO2021008218A CO2021008218A2 CO 2021008218 A2 CO2021008218 A2 CO 2021008218A2 CO 2021008218 A CO2021008218 A CO 2021008218A CO 2021008218 A2 CO2021008218 A2 CO 2021008218A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- methods
- antibodies against
- humanized antibodies
- chain region
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 101000844040 Homo sapiens T cell receptor beta variable 9 Proteins 0.000 abstract 2
- 102100032166 T cell receptor beta variable 9 Human genes 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000009258 tissue cross reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención se refiere a un anticuerpo humanizado monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a la familia TRBV9 del receptor de células T humanas. La invención también se refiere a un ácido nucleico que codifica dicho anticuerpo o fragmento de unión al antígeno del mismo, un vector de expresión, un método para preparar dicho anticuerpo, y el uso de dicho anticuerpo en el tratamiento de las enfermedades o trastornos asociados con la familia de receptores de células T humanas. La invención se dirige a la generación de anticuerpos que se pueden usar para tratar, en particular AS, enfermedad celíaca y enfermedades sanguíneas malignas, cuya patogénesis involucra los TCR de la familia TRBV9.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018146031A RU2712251C1 (ru) | 2018-12-25 | 2018-12-25 | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
| PCT/RU2020/050024 WO2020139175A2 (ru) | 2018-12-25 | 2020-02-20 | Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021008218A2 true CO2021008218A2 (es) | 2021-07-30 |
Family
ID=69184123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0008218A CO2021008218A2 (es) | 2018-12-25 | 2021-06-23 | Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso |
| CONC2021/0009689A CO2021009689A2 (es) | 2018-12-25 | 2021-07-23 | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0009689A CO2021009689A2 (es) | 2018-12-25 | 2021-07-23 | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220112286A1 (es) |
| EP (1) | EP3907239A4 (es) |
| JP (1) | JP2022532274A (es) |
| KR (2) | KR20210119404A (es) |
| CN (2) | CN113646333A (es) |
| AR (1) | AR117734A1 (es) |
| AU (1) | AU2020204492A1 (es) |
| BR (1) | BR112021012555A2 (es) |
| CA (2) | CA3127767A1 (es) |
| CL (1) | CL2021001705A1 (es) |
| CO (2) | CO2021008218A2 (es) |
| CR (1) | CR20210354A (es) |
| EA (1) | EA202191813A1 (es) |
| EC (1) | ECSP21046333A (es) |
| IL (1) | IL284370A (es) |
| JO (1) | JOP20210169A1 (es) |
| MA (1) | MA53689B1 (es) |
| MX (1) | MX2021007719A (es) |
| PE (1) | PE20220217A1 (es) |
| PH (1) | PH12021551532A1 (es) |
| RU (1) | RU2712251C1 (es) |
| SG (1) | SG11202106975VA (es) |
| TW (1) | TW202039574A (es) |
| WO (2) | WO2020091635A2 (es) |
| ZA (1) | ZA202104357B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN116510006A (zh) * | 2022-01-31 | 2023-08-01 | 拜奥卡德联合股份公司 | 抗trbv9抗体的药物组合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766947A (en) | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| US20100330571A1 (en) * | 2009-06-25 | 2010-12-30 | Robins Harlan S | Method of measuring adaptive immunity |
| EP3202784A1 (en) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | T-cell receptor sequences for active immunotherapy |
| RU2694412C9 (ru) | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
-
2018
- 2018-12-25 RU RU2018146031A patent/RU2712251C1/ru active
-
2019
- 2019-12-23 AR ARP190103840A patent/AR117734A1/es unknown
- 2019-12-24 CA CA3127767A patent/CA3127767A1/en active Pending
- 2019-12-24 WO PCT/RU2019/050258 patent/WO2020091635A2/ru active Application Filing
- 2019-12-24 TW TW108147432A patent/TW202039574A/zh unknown
- 2019-12-24 KR KR1020217023541A patent/KR20210119404A/ko not_active Application Discontinuation
- 2019-12-24 CN CN201980092905.7A patent/CN113646333A/zh active Pending
-
2020
- 2020-02-20 MX MX2021007719A patent/MX2021007719A/es unknown
- 2020-02-20 BR BR112021012555-8A patent/BR112021012555A2/pt unknown
- 2020-02-20 SG SG11202106975VA patent/SG11202106975VA/en unknown
- 2020-02-20 JO JOP/2021/0169A patent/JOP20210169A1/ar unknown
- 2020-02-20 KR KR1020217023568A patent/KR20220131489A/ko active Search and Examination
- 2020-02-20 PE PE2021001081A patent/PE20220217A1/es unknown
- 2020-02-20 WO PCT/RU2020/050024 patent/WO2020139175A2/ru unknown
- 2020-02-20 CN CN202080016346.4A patent/CN114144432A/zh active Pending
- 2020-02-20 CA CA3124813A patent/CA3124813A1/en active Pending
- 2020-02-20 AU AU2020204492A patent/AU2020204492A1/en active Pending
- 2020-02-20 EP EP20734640.4A patent/EP3907239A4/en active Pending
- 2020-02-20 CR CR20210354A patent/CR20210354A/es unknown
- 2020-02-20 JP JP2021537707A patent/JP2022532274A/ja active Pending
- 2020-02-20 MA MA53689A patent/MA53689B1/fr unknown
- 2020-02-20 EA EA202191813A patent/EA202191813A1/ru unknown
- 2020-02-20 US US17/417,686 patent/US20220112286A1/en active Pending
-
2021
- 2021-06-23 CO CONC2021/0008218A patent/CO2021008218A2/es unknown
- 2021-06-24 EC ECSENADI202146333A patent/ECSP21046333A/es unknown
- 2021-06-24 IL IL284370A patent/IL284370A/en unknown
- 2021-06-24 ZA ZA2021/04357A patent/ZA202104357B/en unknown
- 2021-06-24 CL CL2021001705A patent/CL2021001705A1/es unknown
- 2021-06-25 PH PH12021551532A patent/PH12021551532A1/en unknown
- 2021-07-23 CO CONC2021/0009689A patent/CO2021009689A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
| EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| CO2021008218A2 (es) | Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano, y sus métodos de uso | |
| CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| BR112016024214A2 (pt) | anticorpos antigênicos anti-tf humanizados | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| CL2019000426A1 (es) | Anticuerpo o un fragmento de unión a antígeno del mismo, capaz de unirse a un receptor humano de interleucina-6. | |
| ECSP20076576A (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| EA202190504A1 (ru) | Способы лечения псориаза | |
| EA202092497A1 (ru) | Анти-cd27 и анти-pd-l1 антитела и биспецифические конструкции | |
| ECSP19018367A (es) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| EA202092588A1 (ru) | Клетки-естественные киллеры, сконструированные для экспрессии химерных антигенных рецепторов с блокадой иммунных контрольных точек | |
| EA202092743A1 (ru) | Антитела к il36r | |
| AR118787A1 (es) | Moléculas de unión a pd-l1 y uso de las mismas para el tratamiento de enfermedades | |
| AR106658A1 (es) | Moléculas de unión específicas de asct2 y sus usos | |
| AR101721A1 (es) | Anticuerpos y receptores de antígenos quiméricos específicos para cd19 |